Product image of Hemgenix (Etranacogene Dezaparvovec) supplied by GNH India

Hemgenix

Active Ingredient:
Etranacogene Dezaparvovec
Origin:
EU

Hemgenix (Etranacogene Dezaparvovec)

Hemgenix is a gene‑therapy product whose active ingredient is etranacogene dezaparvovec, supplied as a vector solution for intravenous infusion. It is authorized in the European Union for prescription use. The therapy delivers a functional factor IX gene via an adeno‑associated virus (AAV) vector, enabling patients with hemophilia B to produce clotting factor IX endogenously. The treatment is administered as a single infusion and is intended for patients with severe factor IX deficiency.

Manufacturer / TM Owner

Csl Behring Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Indications & Clinical Uses

Hemgenix is indicated for the long‑term management of hemophilia B, a genetic deficiency of clotting factor IX.

  • Patients with severe hemophilia B (factor IX activity less than 1%).
  • Patients with moderately severe hemophilia B (factor IX activity 1–5%).
  • Individuals who have developed inhibitors to factor IX replacement therapy.
  • Patients for whom regular factor IX infusions are impractical.
  • Use as part of a comprehensive hemophilia care program.

Side Effects

Common side effects are generally mild and related to the infusion process.

Common

  • Transient fever or chills.
  • Headache.
  • Fatigue or malaise.
  • Nausea or mild gastrointestinal upset.
  • Transient elevation of liver enzymes.
  • Mild infusion‑related reactions (e.g., erythema, itching).

Serious

  • Thrombotic events.
  • Severe liver injury or hepatitis.
  • Immune‑mediated reactions, including anaphylaxis.
  • Insertional mutagenesis (theoretical risk).
  • Development of neutralizing antibodies against the AAV vector.
  • Severe hypersensitivity reactions.

Precautions & Warnings

Patients should be evaluated carefully before receiving Hemgenix.

  • Screen for pre‑existing AAV antibodies that could reduce efficacy.
  • Monitor liver function tests before and after infusion.
  • Use with caution in patients with active hepatitis or liver disease.
  • The safety of Hemgenix in pregnancy and lactation is unknown; avoid use unless benefits outweigh risks.
  • Long‑term effects of gene therapy are still being studied; ongoing follow‑up is recommended.
  • Not recommended for individuals with severe immunodeficiency.
  • Ensure appropriate vaccination status, avoiding live vaccines shortly after infusion.

Avoid Interactions

Hemgenix may interact with other therapies that affect clotting or immune response.

Avoid

  • Concurrent administration of other experimental gene‑therapy products.
  • High‑dose immunosuppressive agents that could impair vector efficacy.

Use with caution

  • Anticoagulants or antiplatelet drugs, which may alter bleeding risk.
  • Other factor IX replacement products, especially during the peri‑infusion period.
  • Live vaccines administered within 4 weeks of infusion.
  • Hepatotoxic medications that could compound liver enzyme elevations.
  • Immunomodulatory therapies that may affect the development of neutralizing antibodies.

Frequently Asked Questions

Hemgenix uses an adeno‑associated virus (AAV) vector to deliver a functional copy of the factor IX gene to liver cells, enabling endogenous production of clotting factor IX.

Eligibility typically includes patients with severe or moderately severe hemophilia B, especially those who have difficulty with regular factor IX infusions or have developed inhibitors to replacement therapy.

Hemgenix is given as a single intravenous infusion under medical supervision. The exact infusion rate and monitoring protocol are determined by the treating physician.

Patients are usually monitored for liver function tests, factor IX activity levels, and signs of immune reactions during the first weeks and periodically thereafter.

The safety of Hemgenix in pregnant or breastfeeding women has not been established, so it is generally avoided unless the potential benefit outweighs the risk.

Common side effects include mild fever, headache, fatigue, nausea, transient elevation of liver enzymes, and mild infusion‑related reactions such as itching or erythema.

Serious risks, though rare, can include thrombotic events, severe liver injury, immune‑mediated reactions like anaphylaxis, and the theoretical risk of insertional mutagenesis.

Concurrent use of other factor IX products should be coordinated with the treating physician, as it may affect the assessment of Hemgenix efficacy and safety.

Hemgenix is designed as a one‑time treatment, but long‑term follow‑up is required to assess durability of factor IX expression and determine if additional interventions are needed.

The vector solution should be stored according to the manufacturer’s instructions, typically at controlled refrigerated temperatures, and protected from light.

Reimbursement varies by country and health‑care system; patients should consult local health authorities or insurance providers for coverage details.

Patients should seek immediate medical attention, report the reaction to their healthcare provider, and follow emergency protocols for anaphylaxis or other serious events.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Etranacogene Dezaparvovec

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT